IRONWOOD PHARMACEUTICALS INC
Ironwood Pharmaceuticals is a biotechnology company that develops and commercializes therapies for people with gastrointestinal and rare diseases. Its commercial product, LINZESS (linaclotide), treats irritable bowel syndrome with constipation, chronic idiopathic constipation and, for some age groups, functional constipation. It is marketed as LINZESS in the United States and several other countries, and as CONSTELLA in Canada and certain European countries. Ironwood shares U.S. development and commercialization of linaclotide with AbbVie and licenses or partners with AbbVie, Astellas and AstraZeneca for other territories. Ironwood is advancing apraglutide, a long-acting synthetic peptide for short bowel syndrome patients dependent on parenteral support, and is conducting a confirmatory Phase III trial program. The company earns money through collaborative arrangements, including sharing U.S. linaclotide development costs and net profits or losses with AbbVie, and receiving royalties and milestone payments from partners. Ironwood is headquartered in Boston, Massachusetts.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No SEC Form 4 filings for $IRWD in the last 30 days.
See all $IRWD insider activity →Ironwood Pharmaceuticals reported Q3 Non-GAAP EPS of $0.36, beating estimates by $0.05, with revenue of $133.04M, up 9.0% Y/Y and $11.47M above expectations. The company raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion, a 35%+ increase Y/Y, and increased total 2026 revenue guidance.
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance – Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 -
Ironwood Pharmaceuticals (IRWD) appointed Tammi Gaskins as CEO effective January 1, 2027, replacing Thomas McCourt, who will retire as CEO but remain on the board. Gaskins, currently the company's Chief Commercial Officer, will also join the board, increasing its size to nine members.
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning IRWD (IRONWOOD PHARMACEUTICALS INC). Coverage has skewed bullish: 6 bullish, 0 neutral, and 0 bearish.
Recent IRWD coverage spans earnings, corporate actions and technology.
Earnings beat and raised full‑year guidance suggest stronger demand for LINZESS and improved profitability.
Guidance raise suggests stronger demand and profitability, likely supporting the stock.
Leadership transition may cause short‑term uncertainty but limited immediate price impact.
Leadership transition may affect investor sentiment and strategic direction.
Guidance raise and balance-sheet actions (retired $200M convertibles) likely support near-term sentiment, while STARS-2 ramp and demand softening risk remain key swing factors.
AlphAI scores every news story that mentions IRWD with an AI model for sentiment and relevance, and aggregates insider trades from IRONWOOD PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Ironwood Pharmaceuticals reported Q3 Non-GAAP EPS of $0.36, beating estimates by $0.05, with revenue of $133.04M, up 9.0% Y/Y and $11.47M above expectations. The company raised its full-year 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion, a 35%+ increase Y/Y, and increased total 2026 revenue guidance.
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises Full-Year 2026 Financial Guidance Driven by Continued LINZESS U.S. Net Sales Growth and Strong Third Quarter Financial Performance – Raises full-year 2026 LINZESS® (linaclotide) U.S. net sales guidance to $1.20 -
Ironwood Pharmaceuticals (IRWD) appointed Tammi Gaskins as CEO effective January 1, 2027, replacing Thomas McCourt, who will retire as CEO but remain on the board. Gaskins, currently the company's Chief Commercial Officer, will also join the board, increasing its size to nine members.
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Appoints Tammi Gaskins as Chief Executive Officer – Tom McCourt to Retire from CEO Post After 17 Years at Ironwood and Four Decades of Distinguished Industry Leadership Bringing Transformational Medicines to Patients – B
Ironwood Pharmaceuticals (IRWD) reported Q2 2026 results on an earnings call. LINZESS U.S. net sales were $282.3M, up 14% YoY, and full-year guidance was raised to $1.15B-$1.20B. Total revenue was $113.0M, adjusted EBITDA $83.0M, and GAAP net income $51.3M. The company also discussed STARS-2 and balance sheet actions, including $200M convertible note repayment.
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FOR IMMEDIATE RELEASE Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results – Raises full-year 2026 LINZESS ® (linaclotide) U.S. net sales guidance to $1.15 - $1.20 billion, representing greater than 30% increase
Ironwood Pharmaceuticals (IRWD) appointed Dr. Jeffrey Silber as Chief Medical Officer and Head of Research and Drug Development, effective July 20, 2026, replacing retiring Dr. Michael Shetzline, who will advise during transition. IRWD said its confirmatory Phase 3 STARS-2 trial of apraglutide for SBS-IF began in June and is actively recruiting. IRWD shares last traded at $4.08, down 3.09%.
Silver Ronald (PFO & PAO) sold 127,890 shares of IRONWOOD PHARMACEUTICALS INC (IRWD) at $4.52 ($0.58M total) on 2026-07-07 under a Rule 10b5-1 trading plan.
IRONWOOD PHARMACEUTICALS INC (IRWD) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001446847 0001446847 2026-06-16 2026-06-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor
Wells Fargo increased its price target for Ironwood Pharmaceuticals (NASDAQ: IRWD) to $5.00 from $3.00, maintaining an "Equal Weight" rating. This adjustment follows Ironwood's strong guidance for its drug Linzess in fiscal year 2026, projected to achieve U.S. net sales of $1.125 billion to $1.175 billion, driven by pricing tailwinds amid a strategic list price reduction. Despite the positive outlook and other recent developments including a settlement with Ferring International and a Citizens upgrade, Wells Fargo remains cautious, emphasizing the critical importance of Apra's success for the stock's future performance.
